Poseida Therapeutics (CDMO)

San Diego, CA
Hybrid — also manufactures internal programs
CAR-T Cell Therapy Gene Editing
6 confirmed programs · 1 sponsors · Last scored 2026-04-02
58.7
Signal Score
○ FDA Inspections ✓ Clinical Trials (6) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Poseida Therapeutics (CDMO)

Signal Score
58.7/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
San Diego, CA
Modalities
CAR-T, Cell Therapy, Gene Editing
Active Programs
6 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 51.7
6 active programs across 1 sponsors
Modalities: Cell Therapy, Gene Editing, CAR-T
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
6 active programs across 1 sponsors · Modalities: Cell Therapy, Gene Editing, CAR-T · 1 programs in advanced phases (Phase 2/3)
Programs 6
Sponsors1
ModalitiesCAR-T, Cell Therapy, Gene Editing
6 active programs across 1 sponsors
Modalities: Cell Therapy, Gene Editing, CAR-T
1 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06014762 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Recruiting
NCT04960579 P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Recruiting
NCT05239143 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT04249947 P-PSMA-101 CAR-T Cells in the Treatment of Subjects With... PHASE1 Terminated
NCT03741127 Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 PHASE1 Active Not Recruiting
NCT03288493 P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With... PHASE1/PHASE2 Terminated
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability 68.0
Parent company: Roche
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Roche
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: San Diego, CA
Modalities: CAR-T, Cell Therapy, Gene Editing
Capacity assessment: 58.0/100
Sites: San Diego, CA
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: San Diego, CA
Modalities: CAR-T, Cell Therapy, Gene Editing
Capacity assessment: 58.0/100
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs → Gene Editing CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 80.2
CAR-T, Cell Therapy, iPSC, Gene Editing
GenScript
Piscataway, NJ / Nanjing, China
Signal Score: 65.5
CAR-T, Cell Therapy, Gene Editing
CTMC
Houston, TX
Signal Score: 63.0
CAR-T, Cell Therapy, Gene Editing
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.9
CAR-T, Cell Therapy